Medifast (MED) Director Kiai Parsa Buys Stock

What Happened

• Kiai Parsa, a director of Medifast, reported two open-market purchases (code P) on 2026-08-24 totaling 4,329 shares at about $12.00 per share. The transactions reported are 4,211 shares for $50,530 and 118 shares for $1,416, for an aggregate cost of approximately $51,946. These were purchases (acquisitions), not sales.

Key Details

• Transaction date: 2026-08-24; reported on Form 4 filed 2026-08-26 (filed within the typical 2-business-day window).
• Prices reported: $12.00 average; footnote indicates actual prices ranged from $11.99 to $12.00 (F4).
• Shares after transaction: Not specified in the filing.
• Relevant footnotes:
  • F1–F3: Parsa has a pecuniary interest via Steamboat Capital Partners Master Fund, LP and Steamboat Capital Partners II, LP; he is Managing Member of the GP and investment adviser and disclaims beneficial ownership except to the extent of that pecuniary interest.
  • F4: Average price shown; detailed per-share price/quantity info is available on request to the SEC staff, issuer, or a security holder.
• Transaction type code: P = Purchase (open market/private purchase).

Context

• These are straightforward open-market purchases (not option exercises, gifts, or awards). Purchases by insiders are often noted by investors as potentially informative, but they do not by themselves prove a change in company prospects. The filing appears timely and provides footnotes clarifying that some holdings may be associated with funds managed by entities related to Parsa.